Journal
FRONTIERS IN IMMUNOLOGY
Volume 10, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2019.00456
Keywords
chimeric antigen receptor; CRISPR; gene editing; immunotherapy; cancer; CAR T
Categories
Funding
- Science and Technology Development Fund of Macau [FDCT/131/2016/A3, FDCT/0015/2018/A1]
- Guangzhou Science and Technology Program [201807010004]
- Faculty of Health Sciences, University of Macau [SRG2016-00082-FHS]
- National Natural Science Foundation of China [31440041]
Ask authors/readers for more resources
Chimeric antigen receptor (CAR) T cells have shown great promise in the treatment of hematological and solid malignancies. However, despite the success of this field, there remain some major challenges, including accelerated T cell exhaustion, potential toxicities, and insertional oncogenesis. To overcome these limitations, recent advances in CRISPR technology have enabled targetable interventions of endogenous genes in human CAR T cells. These CRISPR genome editing approaches have unleashed the therapeutic potential of CAR T cell therapy. Here, we summarize the potential benefits, safety concerns, and difficulties in the generation of gene-edited CAR T cells using CRISPR technology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available